Xenome Ltd.

CLOSED

Australiawww.xenome.comPrivate1–10 employeesEstablished: 2000-01-01

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2000

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Completed

66.7%

Withdrawn

33.3%

Clinical Trials

Trials sponsored by this organization (3)

A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 with bupivacaine interaction study administered intrathecally in healthy volunteers.

Withdrawn

interventional

44 participants

A randomized, double-blind, placebo-controlled Phase I study to evaluate the safety and tolerability of intrathecally administered single ascending bolus doses of Xen2174 in healthy subjects

Completed

interventional

35 participants

A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 PK/PD study administered intrathecally in healthy volunteers.

Completed

interventional

32 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations

Xenome Ltd.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (3)

A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 with bupivacaine interaction study administered intrathecally in healthy volunteers.

*A randomized, double-blind, placebo-controlled Phase I study to evaluate the safety and tolerability of intrathecally administered single ascending bolus doses of Xen2174 in healthy subjects*

A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 PK/PD study administered intrathecally in healthy volunteers.

Approvals

News

A randomized, double-blind, placebo-controlled Phase I study to evaluate the safety and tolerability of intrathecally administered single ascending bolus doses of Xen2174 in healthy subjects